The Cost of Quality: a Study on Bio/Pharma

Tag : Bio Performance


In Aberdeen's July 2007 benchmark report, The Cost of Quality, itwas shown that Best-in-Class manufacturers have distinctcompetitive advantages in performance metrics. In May and June2008, Aberdeen surveyed 122 additional companies identifyingthemselves as pharmaceutical, biotechnology or blood/biologics,referred to here as bio/pharma.

In addition to addressing performance, bio/pharma companies havethe additional mandate of complying with government regulation andproviding traceability in their operations. This study willinvestigate the different pressures that these manufacturers faceand how they can improve performance while still conforming toregulating bodies so that they may take advantage of practices usedby the Best-in-Class.